APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infectious Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Infectious Vaccines Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchInfectious Vaccines Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Infectious Vaccines Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Infectious Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infectious Vaccines Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Infectious Vaccines Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Infectious Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Infectious Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Infectious Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Infectious Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Infectious Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Infectious Vaccines market include Sanofi Pasteur (France), Johnson and Johnson (U.S.), Novartis AG (Switzerland), Merck and Company (U.S.), Pfizer Inc. (U.S.), GlaxoSmithKline plc. (U.K.), MedImmune LLC (U.S.), Emergent Bio Solutions Inc. (U.S.) and CSL Limited (Australia), among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Infectious Vaccines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Infectious Vaccines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Infectious Vaccines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Infectious Vaccines market size, projected growth trends, production technologies, key applications, and end-use industries.

Infectious Vaccines Segment by Company

Sanofi Pasteur (France)

Johnson and Johnson (U.S.)

Novartis AG (Switzerland)

Merck and Company (U.S.)

Pfizer Inc. (U.S.)

GlaxoSmithKline plc. (U.K.)

MedImmune LLC (U.S.)

Emergent Bio Solutions Inc. (U.S.)

CSL Limited (Australia)

Bavarian Nordic (Denmark)

Infectious Vaccines Segment by Type

Preventive Vaccine

Therapeutic Vaccine

Infectious Vaccines Segment by Application

Adults

Pediatrics

Infectious Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Infectious Vaccines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Infectious Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Infectious Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze Infectious Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infectious Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infectious Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infectious Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Infectious Vaccines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infectious Vaccines industry.

Chapter 3: Detailed analysis of Infectious Vaccines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Infectious Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Infectious Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Infectious Vaccines Industry Trends Table 2. Infectious Vaccines Industry Drivers Table 3. Infectious Vaccines Industry Opportunities and Challenges Table 4. Infectious Vaccines Industry Restraints Table 5. Global Infectious Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Infectious Vaccines Revenue Share by Company (2021-2026) Table 7. Global Infectious Vaccines Sales Volume by Company (k units) & (2021-2026) Table 8. Global Infectious Vaccines Sales Volume Share by Company (2021-2026) Table 9. Global Infectious Vaccines Average Price (US$/unit) of Company (2021-2026) Table 10. Global Infectious Vaccines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Infectious Vaccines Key Company Manufacturing Base & Headquarters Table 12. Global Infectious Vaccines Company, Product Type & Application Table 13. Global Infectious Vaccines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Infectious Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Preventive Vaccine Table 18. Significant Companies of Therapeutic Vaccine Table 19. Global Infectious Vaccines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Infectious Vaccines Sales Volume by Type (2021-2026) & (k units) Table 21. Global Infectious Vaccines Sales Volume by Type (2027-2032) & (k units) Table 22. Global Infectious Vaccines Sales Volume Share by Type (2021-2026) Table 23. Global Infectious Vaccines Sales Volume Share by Type (2027-2032) Table 24. Global Infectious Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Infectious Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Infectious Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Infectious Vaccines Sales Value Share by Type (2021-2026) Table 28. Global Infectious Vaccines Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Adults Table 30. Significant Companies of Pediatrics Table 31. Global Infectious Vaccines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Infectious Vaccines Sales Volume by Application (2021-2026) & (k units) Table 33. Global Infectious Vaccines Sales Volume by Application (2027-2032) & (k units) Table 34. Global Infectious Vaccines Sales Volume Share by Application (2021-2026) Table 35. Global Infectious Vaccines Sales Volume Share by Application (2027-2032) Table 36. Global Infectious Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Infectious Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Infectious Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Infectious Vaccines Sales Value Share by Application (2021-2026) Table 40. Global Infectious Vaccines Sales Value Share by Application (2027-2032) Table 41. Global Infectious Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Infectious Vaccines Sales by Region (2021-2026) & (k units) Table 43. Global Infectious Vaccines Sales Market Share by Region (2021-2026) Table 44. Global Infectious Vaccines Sales by Region (2027-2032) & (k units) Table 45. Global Infectious Vaccines Sales Market Share by Region (2027-2032) Table 46. Global Infectious Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Infectious Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Infectious Vaccines Sales Value Share by Region (2021-2026) Table 49. Global Infectious Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Infectious Vaccines Sales Value Share by Region (2027-2032) Table 51. Global Infectious Vaccines Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Infectious Vaccines Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Infectious Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Infectious Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Infectious Vaccines Sales by Country (2021-2026) & (k units) Table 56. Global Infectious Vaccines Sales Market Share by Country (2021-2026) Table 57. Global Infectious Vaccines Sales by Country (2027-2032) & (k units) Table 58. Global Infectious Vaccines Sales Market Share by Country (2027-2032) Table 59. Global Infectious Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Infectious Vaccines Sales Value Market Share by Country (2021-2026) Table 61. Global Infectious Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Infectious Vaccines Sales Value Market Share by Country (2027-2032) Table 63. Sanofi Pasteur (France) Company Information Table 64. Sanofi Pasteur (France) Business Overview Table 65. Sanofi Pasteur (France) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Sanofi Pasteur (France) Infectious Vaccines Product Portfolio Table 67. Sanofi Pasteur (France) Recent Development Table 68. Johnson and Johnson (U.S.) Company Information Table 69. Johnson and Johnson (U.S.) Business Overview Table 70. Johnson and Johnson (U.S.) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio Table 72. Johnson and Johnson (U.S.) Recent Development Table 73. Novartis AG (Switzerland) Company Information Table 74. Novartis AG (Switzerland) Business Overview Table 75. Novartis AG (Switzerland) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Novartis AG (Switzerland) Infectious Vaccines Product Portfolio Table 77. Novartis AG (Switzerland) Recent Development Table 78. Merck and Company (U.S.) Company Information Table 79. Merck and Company (U.S.) Business Overview Table 80. Merck and Company (U.S.) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Merck and Company (U.S.) Infectious Vaccines Product Portfolio Table 82. Merck and Company (U.S.) Recent Development Table 83. Pfizer Inc. (U.S.) Company Information Table 84. Pfizer Inc. (U.S.) Business Overview Table 85. Pfizer Inc. (U.S.) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 86. Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio Table 87. Pfizer Inc. (U.S.) Recent Development Table 88. GlaxoSmithKline plc. (U.K.) Company Information Table 89. GlaxoSmithKline plc. (U.K.) Business Overview Table 90. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio Table 92. GlaxoSmithKline plc. (U.K.) Recent Development Table 93. MedImmune LLC (U.S.) Company Information Table 94. MedImmune LLC (U.S.) Business Overview Table 95. MedImmune LLC (U.S.) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio Table 97. MedImmune LLC (U.S.) Recent Development Table 98. Emergent Bio Solutions Inc. (U.S.) Company Information Table 99. Emergent Bio Solutions Inc. (U.S.) Business Overview Table 100. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio Table 102. Emergent Bio Solutions Inc. (U.S.) Recent Development Table 103. CSL Limited (Australia) Company Information Table 104. CSL Limited (Australia) Business Overview Table 105. CSL Limited (Australia) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. CSL Limited (Australia) Infectious Vaccines Product Portfolio Table 107. CSL Limited (Australia) Recent Development Table 108. Bavarian Nordic (Denmark) Company Information Table 109. Bavarian Nordic (Denmark) Business Overview Table 110. Bavarian Nordic (Denmark) Infectious Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio Table 112. Bavarian Nordic (Denmark) Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Infectious Vaccines Distributors List Table 116. Infectious Vaccines Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Infectious Vaccines Product Image Figure 2. Global Infectious Vaccines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infectious Vaccines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Infectious Vaccines Sales (2021-2032) & (k units) Figure 5. Global Infectious Vaccines Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Infectious Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Preventive Vaccine Image Figure 10. Therapeutic Vaccine Image Figure 11. Global Infectious Vaccines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Infectious Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Infectious Vaccines Sales Volume Share by Type (2021-2032) Figure 14. Global Infectious Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Infectious Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Infectious Vaccines Sales Value Share by Type (2021-2032) Figure 17. Adults Image Figure 18. Pediatrics Image Figure 19. Global Infectious Vaccines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Infectious Vaccines Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Infectious Vaccines Sales Volume Share by Application (2021-2032) Figure 22. Global Infectious Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Infectious Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Infectious Vaccines Sales Value Share by Application (2021-2032) Figure 25. Global Infectious Vaccines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Infectious Vaccines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Infectious Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Infectious Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Infectious Vaccines Sales Value (2021-2032) & (US$ Million) Figure 30. North America Infectious Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Infectious Vaccines Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Infectious Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Infectious Vaccines Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Infectious Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Infectious Vaccines Sales Value (2021-2032) & (US$ Million) Figure 36. South America Infectious Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Infectious Vaccines Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Infectious Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Infectious Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Infectious Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Infectious Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Infectious Vaccines Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Infectious Vaccines Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Preventive Vaccine
  • Therapeutic Vaccine
Applications
  • Adults
  • Pediatrics
Companies covered
  • Sanofi Pasteur (France)
  • Johnson and Johnson (U.S.)
  • Novartis AG (Switzerland)
  • Merck and Company (U.S.)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc. (U.K.)
  • MedImmune LLC (U.S.)
  • Emergent Bio Solutions Inc. (U.S.)
  • CSL Limited (Australia)
  • Bavarian Nordic (Denmark)

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Infectious Vaccines Sales Value (2021-2032)
  4. 1.2.2 Global Infectious Vaccines Sales Volume (2021-2032)
  5. 1.2.3 Global Infectious Vaccines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Infectious Vaccines Market Dynamics
  1. 2.1 Infectious Vaccines Industry Trends
  2. 2.2 Infectious Vaccines Industry Drivers
  3. 2.3 Infectious Vaccines Industry Opportunities and Challenges
  4. 2.4 Infectious Vaccines Industry Restraints
3 Infectious Vaccines Market by Company
  1. 3.1 Global Infectious Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global Infectious Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global Infectious Vaccines Sales Volume by Company (2021-2026)
  4. 3.4 Global Infectious Vaccines Average Price by Company (2021-2026)
  5. 3.5 Global Infectious Vaccines Company Ranking (2024-2026)
  6. 3.6 Global Infectious Vaccines Company Manufacturing Base and Headquarters
  7. 3.7 Global Infectious Vaccines Company Product Type and Application
  8. 3.8 Global Infectious Vaccines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Infectious Vaccines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Infectious Vaccines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Infectious Vaccines Market by Type
  1. 4.1 Infectious Vaccines Type Introduction
  2. 4.1.1 Preventive Vaccine
  3. 4.1.2 Therapeutic Vaccine
  4. 4.2 Global Infectious Vaccines Sales Volume by Type
  5. 4.2.1 Global Infectious Vaccines Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Infectious Vaccines Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Infectious Vaccines Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Infectious Vaccines Sales Value by Type
  9. 4.3.1 Global Infectious Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Infectious Vaccines Sales Value by Type (2021-2032)
  11. 4.3.3 Global Infectious Vaccines Sales Value Share by Type (2021-2032)
5 Infectious Vaccines Market by Application
  1. 5.1 Infectious Vaccines Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Pediatrics
  4. 5.2 Global Infectious Vaccines Sales Volume by Application
  5. 5.2.1 Global Infectious Vaccines Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Infectious Vaccines Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Infectious Vaccines Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Infectious Vaccines Sales Value by Application
  9. 5.3.1 Global Infectious Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Infectious Vaccines Sales Value by Application (2021-2032)
  11. 5.3.3 Global Infectious Vaccines Sales Value Share by Application (2021-2032)
6 Infectious Vaccines Regional Sales and Value Analysis
  1. 6.1 Global Infectious Vaccines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Infectious Vaccines Sales by Region (2021-2032)
  3. 6.2.1 Global Infectious Vaccines Sales by Region: 2021-2026
  4. 6.2.2 Global Infectious Vaccines Sales by Region (2027-2032)
  5. 6.3 Global Infectious Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Infectious Vaccines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Infectious Vaccines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Infectious Vaccines Sales Value by Region (2027-2032)
  9. 6.5 Global Infectious Vaccines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Infectious Vaccines Sales Value (2021-2032)
  12. 6.6.2 North America Infectious Vaccines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Infectious Vaccines Sales Value (2021-2032)
  15. 6.7.2 Europe Infectious Vaccines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Infectious Vaccines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Infectious Vaccines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Infectious Vaccines Sales Value (2021-2032)
  21. 6.9.2 South America Infectious Vaccines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Infectious Vaccines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Infectious Vaccines Sales Value Share by Country, 2025 VS 2032
7 Infectious Vaccines Country-level Sales and Value Analysis
  1. 7.1 Global Infectious Vaccines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Infectious Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Infectious Vaccines Sales by Country (2021-2032)
  4. 7.3.1 Global Infectious Vaccines Sales by Country (2021-2026)
  5. 7.3.2 Global Infectious Vaccines Sales by Country (2027-2032)
  6. 7.4 Global Infectious Vaccines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Infectious Vaccines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Infectious Vaccines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Infectious Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Infectious Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Infectious Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Infectious Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Infectious Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Infectious Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Infectious Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Infectious Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Infectious Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Infectious Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Infectious Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Infectious Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Infectious Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Infectious Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Infectious Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Infectious Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Infectious Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Infectious Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Infectious Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Infectious Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Infectious Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Infectious Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Infectious Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Infectious Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Infectious Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Infectious Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Infectious Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Infectious Vaccines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Infectious Vaccines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Infectious Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi Pasteur (France)
  2. 8.1.1 Sanofi Pasteur (France) Company Information
  3. 8.1.2 Sanofi Pasteur (France) Business Overview
  4. 8.1.3 Sanofi Pasteur (France) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Pasteur (France) Infectious Vaccines Product Portfolio
  6. 8.1.5 Sanofi Pasteur (France) Recent Developments
  7. 8.2 Johnson and Johnson (U.S.)
  8. 8.2.1 Johnson and Johnson (U.S.) Company Information
  9. 8.2.2 Johnson and Johnson (U.S.) Business Overview
  10. 8.2.3 Johnson and Johnson (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Johnson and Johnson (U.S.) Infectious Vaccines Product Portfolio
  12. 8.2.5 Johnson and Johnson (U.S.) Recent Developments
  13. 8.3 Novartis AG (Switzerland)
  14. 8.3.1 Novartis AG (Switzerland) Company Information
  15. 8.3.2 Novartis AG (Switzerland) Business Overview
  16. 8.3.3 Novartis AG (Switzerland) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Novartis AG (Switzerland) Infectious Vaccines Product Portfolio
  18. 8.3.5 Novartis AG (Switzerland) Recent Developments
  19. 8.4 Merck and Company (U.S.)
  20. 8.4.1 Merck and Company (U.S.) Company Information
  21. 8.4.2 Merck and Company (U.S.) Business Overview
  22. 8.4.3 Merck and Company (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Merck and Company (U.S.) Infectious Vaccines Product Portfolio
  24. 8.4.5 Merck and Company (U.S.) Recent Developments
  25. 8.5 Pfizer Inc. (U.S.)
  26. 8.5.1 Pfizer Inc. (U.S.) Company Information
  27. 8.5.2 Pfizer Inc. (U.S.) Business Overview
  28. 8.5.3 Pfizer Inc. (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Inc. (U.S.) Infectious Vaccines Product Portfolio
  30. 8.5.5 Pfizer Inc. (U.S.) Recent Developments
  31. 8.6 GlaxoSmithKline plc. (U.K.)
  32. 8.6.1 GlaxoSmithKline plc. (U.K.) Company Information
  33. 8.6.2 GlaxoSmithKline plc. (U.K.) Business Overview
  34. 8.6.3 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 GlaxoSmithKline plc. (U.K.) Infectious Vaccines Product Portfolio
  36. 8.6.5 GlaxoSmithKline plc. (U.K.) Recent Developments
  37. 8.7 MedImmune LLC (U.S.)
  38. 8.7.1 MedImmune LLC (U.S.) Company Information
  39. 8.7.2 MedImmune LLC (U.S.) Business Overview
  40. 8.7.3 MedImmune LLC (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 MedImmune LLC (U.S.) Infectious Vaccines Product Portfolio
  42. 8.7.5 MedImmune LLC (U.S.) Recent Developments
  43. 8.8 Emergent Bio Solutions Inc. (U.S.)
  44. 8.8.1 Emergent Bio Solutions Inc. (U.S.) Company Information
  45. 8.8.2 Emergent Bio Solutions Inc. (U.S.) Business Overview
  46. 8.8.3 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Emergent Bio Solutions Inc. (U.S.) Infectious Vaccines Product Portfolio
  48. 8.8.5 Emergent Bio Solutions Inc. (U.S.) Recent Developments
  49. 8.9 CSL Limited (Australia)
  50. 8.9.1 CSL Limited (Australia) Company Information
  51. 8.9.2 CSL Limited (Australia) Business Overview
  52. 8.9.3 CSL Limited (Australia) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 CSL Limited (Australia) Infectious Vaccines Product Portfolio
  54. 8.9.5 CSL Limited (Australia) Recent Developments
  55. 8.10 Bavarian Nordic (Denmark)
  56. 8.10.1 Bavarian Nordic (Denmark) Company Information
  57. 8.10.2 Bavarian Nordic (Denmark) Business Overview
  58. 8.10.3 Bavarian Nordic (Denmark) Infectious Vaccines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Bavarian Nordic (Denmark) Infectious Vaccines Product Portfolio
  60. 8.10.5 Bavarian Nordic (Denmark) Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Infectious Vaccines Value Chain Analysis
  2. 9.1.1 Infectious Vaccines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Infectious Vaccines Sales Mode & Process
  6. 9.2 Infectious Vaccines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Infectious Vaccines Distributors
  9. 9.2.3 Infectious Vaccines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst